Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530594 | 0.84 | BCAT2 (0.68) | BCAT2AOC3ALDH1A1TAAR1LMNA | |
| SCHEMBL1605547 | 0.82 | AOC3 (0.58) | BCAT2AOC3TP53TAAR1 | |
| SCHEMBL1605295 | 0.82 | AOC3 (0.58) | BCAT2AOC3TP53TAAR1 | |
| SCHEMBL7518450 | 0.80 | MTNR1A (0.58) | KDM1AMAOBALDH1A1HTR2ALMNA | |
| SCHEMBL27924275 | 0.80 | BCAT2 (0.49) | BCAT2ALDH1A1 | |
| SCHEMBL3903374 | 0.79 | BCAT2 (0.72) | KDM1ABCAT2LMNA | |
| SCHEMBL29042380 | 0.78 | BCAT2 (0.40) | KDM1AMAOBBCAT2AOC3ALDH1A1 | |
| SCHEMBL16628612 | 0.78 | CA12 (0.55) | KDM1AMAOBLMNAGRIN1GRIN2A | |
| SCHEMBL16628471 | 0.78 | CA12 (0.52) | KDM1AMAOBLMNAGRIN1GRIN2A | |
| Potassium Ion SCHEMBL16628440 | 0.78 | CA12 (0.52) | KDM1AMAOBLMNAGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | KDM1A 2872/4885MAOB 757/4885BCAT2 2217/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KDM1A 913/4885MAOB 233/4885BCAT2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.